Key Takeaways

From the Authors As published in the article
  1. Head-to-head studies of antidepressants in patients with major depressive disorder (MDD) are rare, particularly in those with inadequate response to prior therapy. This study assessed the efficacy of the multimodal antidepressant vortioxetine versus that of the serotonin-norepinephrine reuptake inhibitor desvenlafaxine in patients with MDD experiencing partial response to treatment with a selective serotonin reuptake inhibitor.
  2. Vortioxetine was non-inferior to desvenlafaxine in terms of reduction in depression symptom severity assessed using the Montgomery-Asberg Depression Rating Scale.
  3. Vortioxetine-treated patients were significantly more likely to achieve symptomatic and functional remission and reported significantly greater improvements in daily and social functioning and significantly greater satisfaction with their medication than those who received desvenlafaxine.
Extended Takeaways
  1. This was a switch study in a clinically common population: adults aged 18–65 years with major depressive disorder, MADRS total score of ≥24, and only partial response after ≥6 weeks of escitalopram, sertraline, paroxetine, or citalopram, making the findings most applicable to patients with moderate-to-severe residual symptoms after a first SSRI.
  2. The primary symptom outcome showed no meaningful separation after 8 weeks, with a MADRS difference of −0.47 points (95% CI, −1.61 to 0.67; P = .420), so treatment selection may hinge more on functioning, remission, and patient experience than on additional MADRS reduction alone.
  3. Among working patients, vortioxetine produced a greater improvement in overall functioning on the FAST (−16.6 vs −14.1 points; difference, −2.52 [95% CI, −4.88 to −0.15]; P = .037), which is clinically relevant when return to workplace effectiveness is a priority.
  4. Tolerability was broadly similar, but nausea was notably more frequent with vortioxetine (20.0% vs 9.2%), while treatment-emergent adverse events leading to withdrawal remained uncommon in both groups (1.9% and 1.0%, respectively).
  5. The dosing strategy matters for interpretation: vortioxetine was increased to 20 mg/d after 1 week in 99.7% of patients, and 89.0% of those up-titrated stayed on 20 mg/d through week 8, whereas desvenlafaxine remained at 50 mg/d throughout.
  6. Baseline burden was substantial despite prior SSRI treatment, with mean CGI-S and FAST scores of 4.5 and 41.5 and Q-LES-Q domain scores ranging from 28.7% to 42.6%, underscoring the extent of persistent functional impairment and poor quality of life in partial responders.
Read full article
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe